Venous thromboembolism in the pediatric population

Orthopedics

Volumn 33, Issue 3, 2010, Pages

  Oschman, Alexandra ^a   Kuhn, Robert J ^a  

^a UK HealthCare ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; DALTEPARIN; ENOXAPARIN; FIBRINOGEN; HEPARIN; PANTON VALENTINE LEUKOCIDIN; PLASMIN; PREKALLIKREIN; PROTEIN C; PROTEIN S; REVIPARIN; THROMBIN; TINZAPARIN; VON WILLEBRAND FACTOR; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ARM; BACTERIAL VIRULENCE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD VESSEL; BOLUS INJECTION; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETERIZATION; CHILD; CONGENITAL HEART DISEASE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISEASE SURVEILLANCE; FEMORAL VEIN; FRACTURE; GESTATIONAL AGE; HEART RIGHT ATRIUM; HEMOSTASIS; HUMAN; ILIAC VEIN; IMMOBILIZATION; INCIDENCE; INFECTION; INFERIOR CAVA VEIN; INJECTION SITE BURNING; INJURY; INTERNAL JUGULAR VEIN; INTERNATIONAL NORMALIZED RATIO; LEG; NEOPLASM; OSTEOMYELITIS; PARTIAL THROMBOPLASTIN TIME; PREMATURITY; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCORING SYSTEM; SEPSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUBCLAVIAN VEIN; SUPERIOR CAVA VEIN; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT DURATION; RISK ASSESSMENT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CHILD; HEMOSTASIS; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; WARFARIN;

EID: 77949295048     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20100129-23     Document Type: Review

References (18)

1. Parasuraman S, Goldhaber SZ. Venous thromboembolism in children. Circulation. 2006; 113(2):e12-e16.
2. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the united states from 2001 to 2007 (published online ahead of print September 7, 2009). Pediatrics. 2009; 124(4):1001-1008.
3. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombic therapy in children: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004; 126(3 suppl):645S-687S.
4. Sandoval JA, Sheehan MP, Stonerock CE, Shafique S, Rescorla FJ, Dalsing MC. Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population risk (published online ahead of print March 4, 2008). J Vasc Surg. 2008; 47(4):837-843.
5. Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in neonates and children: data from the national hospital discharge survey. J Pediatr. 2004; 145(4):565-565.
6. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990; 12(1):95-104.
7. Ewenstein BM, Van Cott E. Case 6-1998: A six-year old boy with both pain and a bloody effusion in the right hip. N Engl J Med. 1998; 338:532-539.
8. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis (published online ahead of print May 18, 2004). Int Care Med. 2004; 30(6):1032-1040.
9. Crary SE, Buchanan GR, Drake CE, Journeycake JM. Venous thrombosis and thromboembolism in children with osteomyelitis. J Pediatr. 2006; 149(4):537-541.
10. Martínez-Aguilar G, Avalos-Mishaan A, Hulten K, Hammerman W, Mason EOJ, Kaplan SL. Community-acquired, methicillin-resistant and methicillin-susceptible staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J. 2004; 23(8):701-706.
11. Gonzalez BE, Teruya J, Mahoney DH, et al. Venus thrombosis associated with staphylococcal osteomyelitis in children. Pediatrics. 2006; 117:1673-1679.
12. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997; 350(9094):1795-1798.
13. Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003; 349(13):1227-1235.
14. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994; 35(1):78-83.
15. Nowak-Göttl U, Bidlingmaier C, Krümpel A, Göttl L, Kenet G. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants, and children (published online ahead of print October 1, 2007). Br J Pharmacol. 2008; 153(6):1120-1127.
16. Massicotte P, Julian JA, Marzinotto V, et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thrombosis Research. 2003; 109(2-3):93-99.
17. Michaels LA, Gurian M, Hegyi T, Drachtman RA. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics. 2004; 114(3):703-707.
18. Malowany JI, Hons BH, Knoppert DC, Chan AK, Pepelassis D, Lee DS. Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Pharmacotherapy. 2007; 27(9):1263-1271.